Biological significance of FoxN1 gain-of-function mutations during T and B lymphopoiesis in juvenile mice

L Ruan 1,2,3, Z Zhang 2,3, L Mu 2, P Burnley 2, L Wang 2, B Coder 2, Q Zhuge 1 and D-M Su 1,2

FoxN1 is cell-autonomously expressed in skin and thymic epithelial cells (TECs), essential for their development. Inborn mutation of FoxN1 results in hair follicle and TEC development failure, whereas insufficient postnatal FoxN1 expression induces thymic atrophy, resulting in declined T lymphopoiesis. Although upregulating FoxN1 expression in the aged FoxN1-declined thymus rejuvenates T lymphopoiesis, whether its over- and ectopic-expression in early life is beneficial for T lymphopoiesis is unknown. Using our newly generated Rosa26-STOP FoxN1 mice, in which over- and ectopic-expression of FoxN1 can be induced by various promoter-driven Cre-mediated deletions of the roadblock STOP in early life, we found that K14Cre-mediated inborn FoxN1 overexpression induced neonatal lethality, exhibited abnormal permeability in the skin and abnormal nursing. Ubiquitous deletion of the STOP mediated by progressive uCreERT leakage in juvenile mice affected thymus and bone marrow normality, resulting in an increased ratio of medullary/cortical TECs, along with declined T and B lymphopoiesis. Although the K5CreERT-mediated FoxN1 overexpression mice had a normal lifespan, induction of K5CreERT activation in juveniles adversely influenced total thymocyte development and produced ichthyosis-like skin. Therefore, FoxN1 has temporal and tissue-specific activity. Over- and ectopic-expression of FoxN1 in early life adversely influence immature TEC, T and B cell, and skin epithelial development. Cell Death and Disease (2014) 5, e1457; doi:10.1038/cddis.2014.432; published online 9 October 2014

Transcription factor FoxN1 is an epithelial cell-autonomous gene, predominantly regulating development of thymic epithelial cells (TECs) and skin keratinocytes. Inborn FoxN1 mutation results in thymic and hair follicle epithelial development failure associated with primary immune deficiency and hairless nude skin. Insufficient FoxN1 expression in postnatal life results in accelerated thymic aging. Although elevating FoxN1 expression in the aged thymus can reinstate TEC homeostasis and induce thymic functional rejuvenation, whether FoxN1 activity is sensitive to genetic dosage, tissue, and temporal-specificity is still unclear. Mounting evidence shows that dosage of FoxN1 is indeed important for postnatal thymic homeostasis. When dosage of FoxN1 is slightly elevated or depressed, the status of the postnatal thymus is significantly influenced. It is known that the thymus in wild-type (WT) young mice with a full dosage of FoxN1 is completely normal, whereas it is completely abnormal in FoxN1-null (inborn mutation, termed nu/nu) nude mice. In between these two extremes, the FoxN1-null heterozygote (nu+/+) mouse has a 50% reduced genetic dosage compared to its WT littermates. Although the 50% dosage of FoxN1 is sufficient to induce TEC patterning during thymic organogenesis, the nu/+ mice have certain defects in thymic size and thymocyte number, particularly as age increases, compared with WT littermates. When FoxN1 was reduced by ~30% compared to its WT levels in the postnatal thymus, thymic atrophy was significantly induced. On the other hand, when FoxN1 dosage was increased by infusing minuscule amounts of vector-carried FoxN1 cDNA into a naturally aged thymus, it resulted in significant thymic rejuvenation. Using a Keratin(K)14 promoter-driven FoxN1 transgenic (Tg) mouse model the overexpression of FoxN1-attenuated age-associated thymic involution. Upregulating FoxN1 specifically in TECs (via inducible FoxN1ER Tg) in the aged fully involuted thymus confirmed the effect of reversing the involution. These experiments demonstrated that age-related thymic involution is causally associated with the loss of FoxN1. However, whether the dosage of FoxN1 can be regarded as ‘the more, the better’ for promoting thymic development is arguable. In addition, another recent report using the same K14-FoxN1 transgenic mice showed that FoxN1 expressed in the bone marrow (BM) of K14 stroma, which is not a prominent site of FoxN1 expression, promoted T-lineage production, but
inhibited B-lineage production. Therefore, another question about the role of FoxN1 in nonprominent locations arises.

We addressed these questions using an inducible FoxN1 expression mouse model—the *Rosa26-STOP^fox−FoxN1* transgenic mouse. In this mouse, the *FoxN1* mediated deletion of the roadblock *STOP* early gene enhancer/chicken β-actin promoter (pCAG). This induces overexpression of exogenous FoxN1 in mice with Cre-mediated deletions of the roadblock *STOP* FoxN1 over-expression (or nonprominent location expression) in early life stages adversely affected the development of the skin, thymus, and T cells, as well as B cells, whereas K5CreER^T^-mediated FoxN1 overexpression in adult mice did not cause any observable defects, and can probably be expected to attenuate age-related thymic involution as reported. Therefore, FoxN1 exhibits both temporal and tissue-specific activity.

**Results**

The characteristics of *Rosa26-STOP^fox−FoxN1* mouse model. We generated an inducible exogenous FoxN1 expression mouse model, the *Rosa26-STOP^fox−FoxN1* transgenic mouse, to study the biological significance of over- and ectopic-expression of FoxN1. In this mouse, the flag-FoxN1 cDNA (kindly provided by Dr. Brissette) driven by a pCAG promoter (kindly provided by Dr. McMahon) was inserted into the *Rosa26* locus. This fragment was book-ended by a *STOP* roadblock cassette and IRES-GFP reporter gene, respectively (Supplementary Figure S1A). The DNA construct was verified by sequencing. This makes conditional expression of the FoxN1 transgene controlled by tissue-specific Cre/CereRT^T^ genes. We first selected K14Cre to mediate the removal of the roadblock, because K14^+^ epithelial cells are epithelial progenitor cells in the skin, lung, and breast epithelial basal layer, and FoxN1 is a regulator that controls skin and thymic epithelial progenitor cell differentiation. We found that newborn mice with both *Rosa26-STOP^fox−FoxN1* and K14Cre transgenes (termed FoxN1^TgK14Cre^+^) had strong FoxN1 and GFP expression (Supplementary Figures S1B and C) in the skin and thymus.

To verify the targeted locus, Southern blot for *Rosa26-STOP^fox−FoxN1* mouse genomic DNA was performed. The results of correct genomic DNA size (with EcoRV digestion) are shown in Supplementary Figure S1D. To verify whether this exogenous FoxN1 is functional, we crossed the *Rosa26-STOP^fox−FoxN1* mice with FoxN1^fox−K5CreER^T^ conditional gene knockouts (cKO) mice to get FoxN1^Tg^, FoxN1^fox^ cKO mice. In this mouse, tamoxifen (TM) induction via K5CreER^T^ conditionally knocks out endogenous FoxN1 while inducing exogenous FoxN1 expression. We found that the FoxN1^Tg^, FoxN1^fox^ cKO mice had a normal thymus (data not shown), whereas FoxN1^fox^ cKO mice alone had an atrophied thymus, indicating FoxN1^Tg^ has normal FoxN1 activity that can compensate for the loss of FoxN1^fox^ in the thymus.

Unfortunately, FoxN1^TgK14Cre^+ mice cannot survive for more than 24 h after birth. The mice had opened eyes from later gestation until birth compared to their FoxN1^TgK14Cre^+ (nonexogenous FoxN1 expression) littermates (Supplementary Figure S1E).

**Neonatal FoxN1^TgK14Cre^+ mice had increased skin permeability and defect in nursing.** In order to determine what causes FoxN1^TgK14Cre^+ neonatal death, we focused on water intake and retention, because our neonatal mice share similar phenotypes with the involucrin promoter-driven FoxN1 transgenic neonatal mice, which possess open eyes at birth and neonatal lethal phenotype with dehydration. Using an O-galactopyranoside (X-gal) staining approach, which is one of the skin barrier function assays used for determining skin permeability, we found that FoxN1^TgK14Cre^+ newborn skin permeability was increased, mostly focused around the eye region (arrows in Figure 1a). The increased region of skin permeability was consistent with the open-eye phenotype. We also found that these newborn mice cannot nurse by checking their stomach (Figure 1b). In addition, the microstructure of FoxN1^TgK14Cre^+ newborn skin showed increased thickness in the epidermal layer (blue arrow in Figure 1c) and flattened structure in the muscle layer (red arrow in Figure 1c), which are related to dehydration and flexibility in the stratum corneum. The structure looks similar to the changes seen in congenital ichthyosis, but not as severe. These phenotypes suggest that FoxN1 overexpression in K14^+^ epithelium of the skin induces developmental mutations that result in an increase in skin permeability and defect in nursing. Therefore, FoxN1^TgK14Cre^+ neonates die from dehydration.

**Overexpression of exogenous FoxN1Tg, mediated by uCreER^T^ in juveniles, adversely affects thymus juvenile stage maturation.** We next asked whether FoxN1 overexpression influences thymus development and T lymphopoiesis, as the main role of FoxN1 is the regulation of TEC differentiation, which results in an increase in skin permeability and defect in nursing. Therefore, FoxN1^TgK14Cre^+ neonates die from dehydration.

**Abnormal FoxN1 expression hurts lymphopoiesis L Ruan et al**
Abnormal FoxN1 expression hurts lymphopoiesis

L. Ruan et al.

Cell Death and Disease

Figure 1 FoxN1 overexpression mediated by K14Cre\(^+\)-induced defects in skin and nursing in newborn mice. (a) Skin permeability assay with X-gal shows increased permeability, mostly focused around the eyes (blue arrows) of FoxN1\(^Tg\)K14Cre\(^+\) newborn mice; (b) stomachs (blue arrows) of FoxN1\(^Tg\)K14Cre\(^+\) (left) and FoxN1\(^Tg\)K14Cre\(^-\) (right) newborn mice, with little to no milk in the stomach of FoxN1\(^Tg\)K14Cre\(^+\) newborn mouse; and (c) skin histological assay (H&E staining) shows increased thickness in the epidermal layer (blue arrow) and flattening in the muscle layer (red arrow) of FoxN1\(^Tg\)K14Cre\(^+\) newborn mice.
islets to occupy a large region (Figure 2, top panels), and increased the proportion of claudin-3, -4 (Cld3,4+) and UEA-1+ TECs (Figure 2 middle rows), which represent immature (Cld3,4)31 and mature organized mTECs (UEA-1),32 respectively, as well as an increase in Aire+ mTECs (Figure 2 bottom panels). However, the trade-off for enhanced mTEC maturation was defective cTECs, as exhibited by diminished β5t+ dendritic-shaped bright spots that are normally observed in the FoxN1TguCreERT− control thymus (Figure 2, left panel in the second row). β5t is considered a cTEC biomarker33 and is essential for the positive selection of T cell receptor.34,35 Flow cytometry analysis of the ratio of mTECs/cTECs further
confirmed that the proportion of mTECs were increased at the expense of cTECs (Figure 3).

On checking the thymocyte profile, we found that the thymic size (Figure 4a) and weight (Figure 4b) were reduced in the FoxN1 overexpression group. Furthermore, the thymocyte profile was obviously changed compared with control group (Figure 4c), with significantly decreased absolute cell number of total thymocytes (Figure 4d) and all subpopulations (Figure 4e), especially CD4+8+ double positive cells. The results indicate that FoxN1 overexpression in juvenile mice adversely affected thymocyte development by influencing thymic microstructure maturation and potential ectopic expression of FoxN1 in hematopoietic cells via uCreERT2 mediation.

**FoxN1**-uCreERT2 juveniles showed deterioration of T cell function in the periphery. We asked whether reduced thymocyte number, resulting from the overexpression of exogenous FoxN1, affects mature T cell function in the periphery by testing CD4 splenic T cell responsiveness to anti-CD3ε and anti-CD28 costimulation. We noticed that the proportion of splenic T cells were significantly increased (Figures 5a and b), whereas the absolute cell number was significantly decreased (Figure 5c). IL-2 production was significantly decreased in CD4+ splenic T cells in response to costimulation (Figure 5d), implying that the peripheral T cells were functionally impaired in the *FoxN1*+uCreERT2 juvenile mice.

Ectopic expression of exogenous FoxN1, mediated by uCreERT2 in juvenile BM, adversely affects B cell development. We noticed that the *FoxN1*+uCreERT2 juvenile mice had dramatically reduced mass of both the thymus and spleen, and absolute total cell number in both the thymus and spleen (Figure 4a). We also noticed that with the increased proportion of T cells in the spleen (Figure 5a), the proportion of B cells (Figure 6a, top panels) and absolute B cell number (data not shown) in the spleen were significantly decreased. This led us to determine whether defects in B cell development were due to ectopic expression of FoxN1. We noticed that the peripheral T cells were functionally impaired in the *FoxN1*+uCreERT2 juvenile mice.

In order to confirm the expression of FoxN1 in the BM of *FoxN1*+uCreERT2 mice, we checked FoxN1 mRNA level with real-time RT-PCR. We flushed and collected total BM from femurs, depleted red blood cells, then isolated total mRNA with TRIzol reagent, and digested any transgenic DNA contamination via DNase-I enzymatic treatment. Because transgenic FoxN1 cDNA is characterized by the absence of introns in the genomic DNA sequence, PCR products generated using intron-spanning primers cannot differentiate the transgenic cDNA, which is already incorporated into the genomic DNA of the transgenic mice. Therefore, complete removal of DNA with DNase-I before reverse transcription is critical. We determined that FoxN1 was markedly expressed in the BM of *FoxN1*+uCreERT2 juvenile mice (Figure 6b). The results indicate that *FoxN1*+uCreERT2 mice have ectopic FoxN1 expression in the BM following the deletion of STOPlox, mediated by uCreERT2. Moreover, the proportion of CD4+8+ double positive cells was significantly decreased in CD4+ splenic T cells in response to costimulation (Figure 5d), implying that the peripheral T cells were functionally impaired in the *FoxN1*+uCreERT2 juvenile mice. The results indicate that *FoxN1*+uCreERT2 juveniles showed deterioration of T cell function in the periphery.

**FoxN1**+uCreERT2 juveniles showed deterioration of T cell function in the periphery.
observed postnatal FoxN1 gain-of-function mutation-induced newborn lethal phenotype, and the mice have a normal lifespan.

We found, by observing GFP expression in juvenile (2 weeks) thymuses, that Cre-recombinase leakage in K5CreERT was not as strong as in uCreERT (Supplementary Fig. S3). Therefore, we intraperitoneally injected TM into these mice to enhance induction of FoxN1Tg expression in FoxN1TgK5CreERT+ newborn and adult (4–5 weeks) mice (described in Figure 7a). In adult mice we found that following five-time (5 × ) TM-injections, the FoxN1Tg did not result in any adverse phenotypes in the skin and thymus (mass, total thymocyte number, and CD4 versus CD8 profile, Figure 7b). However, in juvenile mice, after x4 TM-injections at the neonatal stage, mild adverse phenotypes were observed in the juvenile thymus, such as reduced thymic mass, total thymocytes, and all subset cell numbers (data not shown), but there was no change in CD4 versus CD8 profile (Figure 7c). However, this induction strategy induced a severe skin phenotype, exhibiting ichthyosis-like coarse skin and hair loss phenotypes (Figures 7d and e). The results suggest that: (1) FoxN1Tg overexpression in the juvenile stage may adversely influence the underdeveloping epithelium, whereas it may not affect or may even be beneficial for mature epithelial tissues in adults;15 (2) this adverse effect is more severe in the skin than in the thymus.

Discussion

The biological significance of inborn and postnatal loss-of-function mutations in the FoxN1 gene has been studied for...
Rosa26-STOP K14Cre-mediated and B cell, and skin epithelial development. We found that expression of FoxN1 in early life influences immature TEC, T biologically significant evidence that over- and ectopic-in panels B and C); and (d) dot plots on the left show a representative flow cytometric experiment of splenic IL-2 T cells in CD4+ population gate in response to costimulation from anti-CD3ε and anti-CD28, whereas the panel on the right shows summary of CD4+IL-2+ T cells in the spleen in response to costimulation from anti-CD3ε and anti-CD28 (seven animals in each group). * = statistically significant; ** = statistically very significant.

Figure 5  T cells in FoxN1TgCreERT+ juvenile mice increased %, reduced absolute number, and declined responsiveness. (a) Representative flow cytometric gates of splenic CD3+ T cells; (b) summarized results of the percentages of CD3+ T cells in the spleen; (c) summarized results of absolute CD3+ T cell number per spleen (n = number of animals in panels B and C); and (d) dot plots on the left show a representative flow cytometric experiment of splenic IL-2 T cells in CD4+ population gate in response to costimulation from anti-CD3ε and anti-CD28, whereas the panel on the right shows summary of CD4+IL-2+ T cells in the spleen in response to costimulation from anti-CD3ε and anti-CD28 (seven animals in each group). * = statistically significant; ** = statistically very significant.

several decades. However, the biological significance of inborn and postnatal FoxN1 gain-of-function mutations has just begun to be probed. In this report, we used our newly developed inducible tissue-specific mouse model for FoxN1 gain-of-function mutations to establish biologically significant evidence that over- and ectopic-expression of FoxN1 in early life influences immature TEC, T and B cell, and skin epithelial development. We found that K14Cre-mediated Rosa26-STOPFoxN1Tg newborns had a neonatal lethal phenotype caused by dehydration due to abnormal permeability in the skin and defect in nursing. These neonatal mice shared similar phenotypes with the involucrin promoter-driven FoxN1 transgenic neonatal mice, which have enhanced ectopic expression of FoxN1. The uCreER1-mediated overexpressed FoxN1 induced by progressive leakage of Cre-recombinase beyond the neonatal stage affected the development of the thymus, thymocytes, and BM in the juvenile stage, indicating that TEC development skewed towards mTECs, thymocyte numbers were significantly decreased in all subsets, a proportion of peripheral T cells was increased but the absolute number and functional response were significantly reduced, and the numbers of BM and peripheral B cells were significantly decreased. However, KSCreERT1-mediated FoxN1 overexpression via TM induction in the adults resulted in normal thymus and skin, whereas mice subjected to TM induction as neonates had mildly abnormal development of the thymus, and severe ichthyosis-like skin in the juvenile mice.

Generally, enhancing FoxN1 expression in an aged thymus should rejuvenate atrophied dysfunction, as FoxN1 is decreased with age. However, no reports thus far looked into whether enhanced FoxN1 expression in the juvenile thymus, which already has high levels of FoxN1, is beneficial for further thymic development. Our report provides a negative answer, in which FoxN1 gain-of-function mutations in juvenile mice (younger than 3 weeks, before weaning) had an adverse effect on thymic development. This adverse effect on the skin occurred early (neonatal stage) and was severe (lethality). Interestingly, these lethal phenotypes were not reported in K14 and K5 promoter-driven FoxN1 transgenic mice made by other groups. This is probably because we used both the Rosa26 promoter to ensure the FoxN1 gene is expressed in all Rosa26 positive tissues (almost ubiquitously), followed by pCAG promoter to ensure strong FoxN1 expression. The pCAG promoter is a CMV-EIE enhancer plus chicken β-actin promoter sequence, which was confirmed to be able to drive enhanced gene expression, particularly in the cutaneous epithelium, which may explain why the skin phenotype is so strong. However, upregulating FoxN1 in later life stage via inducible pCAG-FoxN1ER mediated by FoxN1-
Cre Tg, which achieves overexpressing exogenous FoxN1 only in endogenous FoxN1-declined TECs, is beneficial to rejuvenation of aged thymic function. We did not observe defects during thymic development induced by FoxN1 gain-of-function mutations in the prenatal thymus in our K14-, K5-, and ubiquitous Cre-mediated FoxN1 overexpressing mice. Therefore, the dosage of FoxN1 could be considered ‘the more, the better’ in the prenatal thymus. However, FoxN1 gain-of-function mutations in the early postnatal thymus resulted in defects in TEC development, as observed in the ubiquitous CreERT (continuous Cre-recombinase leaky)-mediated and K5CreERT (juvenile mice with TM x4)-mediated Rosa26-STOPFox–FoxN1Tg mice (Figures 2–4 and 7c). Therefore, the dosage of FoxN1 could not be considered ‘the more, the better’ for juvenile stage thymic development. At this stage, the thymic medulla is still undergoing development, and expression of FoxN1 may be just beginning to decline in the natural thymus, where enhancing FoxN1 expression may break this balance.

However, in the adult and late postnatal thymus, FoxN1+ TECs are markedly reduced. Enhancing FoxN1 expression may produce a beneficial effect that may slow down thymic aging, or at least no harmful effects as shown in our K5CreERT (with TM x5 induction in the adult)-mediated Rosa26-STOPFox–FoxN1Tg transgenic adult mice (Figure 7b). In our uCreERT-mediated Rosa26-STOPFox–FoxN1Tg transgenic juvenile mice, we also found that B lymphopoiesis was markedly decreased in the BM and spleen (Figure 6). This is consistent with the finding in K14 promoter-driven FoxN1 transgenic mice, in which B-lineage cell numbers were significantly lower. It could be caused by exogenous FoxN1 expression in nonprominent locations, not only in BM mesenchymal origin stromal cells but also in hematopoietic origin cells because of ubiquitous CreERT.

In our model, FoxN1 overexpression in the BM not only disrupted B lymphopoiesis, but was also not beneficial for T cell development. In the uCreERT leakage-mediated FoxN1 overexpression in Rosa26-STOPFox–FoxN1Tg juvenile mice,
Figure 7  FoxN1 overexpression mediated by K5CreERT+ produced different outcomes in newborn and adult thymus and skin. (a) Schematic of induced FoxN1 expression with TM in FoxN1TgK5CreERT+ newborn (strategy 1) and adult (strategy-2) mice; (b) the panel on the left shows summary of absolute total thymocyte numbers from 11 FoxN1TgK5CreERT+ and 11 FoxN1TgK5CreERT− control adult mice, injected with TM x5 from adult (see TM induction strategy-2, shown in panel a), whereas flow cytometric dot plots on the right show a representative profile of CD4+ versus CD8+ thymocytes; (c) the two leftmost panels show decreased thymic weight and total thymocyte numbers; the dot plots on the right show a representative profile of CD4+ versus CD8+ thymocytes in FoxN1TgK5CreERT+ juvenile mice injected with TM x4 from birth (see TM induction strategy 1, shown in panel a); (d) skin profile of FoxN1TgK5CreERT+ 2-week-old; and (e) 3-week-old juvenile mice, injected with TM x4 from birth (same as panel c). Image shows ichthyosis-like, coarse skin and hair loss (red arrow) in a representative FoxN1TgK5CreERT+ juvenile mouse. Panel e bottom shows representative H&E staining of microstructure of the skin from a representative FoxN1TgK5CreERT+ 3-week-old juvenile mouse. Double headed white arrows indicate increased thickness in the epidermal layer. ** = statistically very significant.
BM LSK (lineage negative, Sca-1+ and c-kit+) cells, which are T-lymphohematopoietic progenitors in the BM, were decreased (Supplementary Figure S4) and early T-cell thymic progenitor (lineage negative, CD44+CD25−, and c-kit+) cells were increased in percentage (data not show), but decreased in absolute number along with all other thymocyte subpopulations (Figure 4). At least, FoxN1 expression in BM stromal (niche) cells is not critically required for T-cell development, as WT thymic lobes grafted into nude (FoxN1−/−) mice under the kidney capsule, without any modification in the FoxN1−/− host BM niche, are able to generate normal T cells, which is a common model for studying lymphostromal interactions.

The FOXN1 leads to congenital alopecia and an alymphoid thymus with severe combined primary T-cell immunodeficiency,7,44–46 resulting in death in early childhood from severe infections.44,47 Therefore, gene therapy with FOXN1 is one of options to be possibly selected to treat fetal FOXN1 mutations. If so, the dosage of FOXN1, target tissues, and developmental stages must be carefully considered, because our data has demonstrated that over- and ectopic-expression of FoxN1 is pathogenic and potentially lethal. In addition, although there are not any reported diseases predicated on the over- and ectopic-expression of FoxN1, this does not rule out their discovery in the near future. A growing paradigm of microRNAs regulating gene activity is emerging. A recent report has linked silencing of microRNAs (miR-18b and miR-518b) with the upregulation of FoxN1 in embryonic stem cells.48 Evidence to support microRNA mutations affecting gene expression and leading to heritable diseases is emerging with time. Our results provide a clue of potential pathologies that could emerge from mutations in the microRNA or microRNA target regulators that maintain FoxN1 levels.

It is taken for granted that loss-of-function mutations induce defective phenotypes, whereas it is hard to accept that gain-of-function mutations can also induce defective phenotypes. Our results show that neonatal overexpression of FoxN1 mainly affects skin development, which was also demonstrated by an Invulcin promoter-driven FoxN1 transgenic mouse model.54 Our study addressed whether FoxN1 expression in the thymus can be considered ‘the more, the better’. Although it is not the case in certain developmental stages, such as in juveniles, enhancing FoxN1 expression in the FoxN1−/- aged thymus should provide significant rejuvenation.12,14,15 In fact, ectopic-expression of FoxN1 in tissues that do not predominantly express FoxN1, such as the BM, is harmful. The biological significance of gain-of-function mutations in the FoxN1 gene is summarized in Supplementary Figure S5. Ultimately, if FoxN1 is not expressed in the right tissues and right life developmental stages, then physiological abnormalities will be induced. In our models, FoxN1 gain-of-function mutations disrupted B-lymphopoiesis and did not help T lymphopoiesis. FoxN1 possesses developmental stage and tissue-specific activity.

Materials and Methods
Mice, age groups, genotyping, and animal care. Neonatal (1 day) and juvenile (2-3 weeks) mice (C57BL/6 genetic background) were used. Rosa26-STOPFoxN1 transgenic (termed FoxN1+) mice were generated by our laboratory (available upon request),1 and genotyped with three primers (Supplementary Figure S1A). The FoxN1+ mice were crossed with K14Cre,49 K5CreER19,25 and ubiquitously pCAG-CreERT (pCreERT)19 mice (Jackson Laboratories, Bar Harbor, ME, USA, #004782, #018394, and #004682). The FoxN1+/+ (fx) mice carrying a TM-inducible pCreERT (termed fx/Fx-pCreERT) were generated and genotyped as described previously11 (Jackson Laboratories #012941). All animal experiments were performed according to the protocols approved by the Institutional Animal Care and Use Committee of the University of North Texas Health Science Center, in accordance with guidelines from the National Institutes of Health, USA.

Skin permeability assay. Details are described in a previous publication.26 In brief, freshly isolated embryos were rinsed in phosphate buffered saline (PBS) and immersed in X-gal staining reagent overnight at 30°C. On the following day, embryos were rinsed in PBS and photographed.

IF staining. Cryosections (5/6 μm thick) were stained as described previously.50 The primary antibodies used were rabbit anti-FoxN1 (provided by Dr. Itoi),43 anti-claudin-5,45 (Invitrogen, Grand Island, NY, USA, #344700 and #344600), anti-Keratin-5 (Covance, Princeton, NJ, USA, #PRB-160P), Biotinylated-UEA-1 (Vector Laboratories, Burlingame, CA, USA, #01-1065), anti-Aire (Santa Cruz, Dallas, TX, USA, #SC-33189, anti-JPT (Medical and Biological Laboratories, Nagoya, Japan, #PD0211), and anti-Keratin-9 (Troma-1 supernatant). The secondary antibodies used were Cy3-conjugated or Alexa-Fluor-488-conjugated donkey anti-rabbit or -rat IgG (Jackson Immunoresearch Laboratories, West Grove, PA, USA).

Real-time RT-PCR. Total RNA from mouse thymus, spleen, and BM was isolated with TRizol reagent and reverse transcribed to cDNA with the SuperScriptIII cDNA kit (Invitrogen). Real-time RT-PCR was performed with TaqMan reagents. The sequences of FoxN1 primers and probe (TaqMan method) were as described previously.11 The relative expression levels of FoxN1 mRNAs from the thymus, spleen, and BM were internally normalized to GAPDH levels, then compared with a ΔΔCT value from pooled young WT thymuses. This ΔΔCT value was always arbitrarily set as 1.0 in each real-time PCR reaction.

Western blot analysis. The whole thymus was subjected to homogenization and protein extraction in RIPA lysis buffer (Sigma, St. Louis, MO, USA, #R0278). Protein, −25 μg/lane, was loaded under reducing conditions for direct Western blot assay with FoxN1 antibody (1:1000 dilution of primary antibody; 81 KD band) antibodies. GAPDH or β-actin were used as an internal loading control.

Flow cytometry assays. Single cell suspensions of thymocytes, spleen, and BM (flushed from the mouse femur) cells, as well as TECs (isolated with collagenase-V/DNase-I isolation method)50 were stained with combinations of fluorochrome-conjugated antibodies against cell surface markers and/or an intracellular marker, which are indicated in each figure. Data was acquired using a BD LSRII Flow Cytometer (BD Bioscience, San Jose, CA, USA) and analyzed using FlowJo software (Treestar, Inc., Ashland, OR, USA).

Analysis of intracellular IL-2 in peripheral CD4+ T cells in response to costimulation of CD3 and CD28 antibodies. Red blood cell lysis buffer (Sigma, #R7757) treated spleen cells (2 × 10^6 per well) were cultured with anti-mouse CD3ε and CD28 antibodies (2 μg/ml each) supplemented with BD GolgiStop (0.7 μl/ml, from BD Biosciences, #554724) for 5 h. The harvested cells were stained for CD4 on the surface, fixed and permeabilized,12 then stained with fluorochrome-conjugated IL-2 antibody intracellularly, following flow cytometry assay.

Statistics. Statistical significance was analyzed by unpaired Student’s t-test. Differences were considered statistically significant at values of P < 0.05.

Conflict of Interest
The authors declare no conflict of interest.

Acknowledgements. We thank Dr. AP McMahon (USC) for kindly providing pBSApCAGflG vector for the generation of Rosa26-STOPFoxN1+ mice; Dr. Zhijie Liu (UCSD) for supporting mouse generation and discussion of Rosa26-STOPFoxN1+ mouse phenotypes; Dr. JL Brissette (SUNY Downstate Medical Center) for kindly providing FoxN1 cDNA and critically reading the manuscript; and Dr. Manami Itoi (Meiji University, Japan) for kindly providing FoxN1 antibody.
